AR and prostate carcinoma: In 2015, this group used the same method to analyze 77 CTCs obtained from the peripheral blood of 13 prostate cancer patients and found that gene expression in CTCs was heterogeneous and included androgen receptor (AR) mutants and splicing-related differential expression of isomers.